Drug Profile

Research programme: cMET:EGFR bi-specific centyrin based therapeutics - Aro Biotherapeutics

Alternative Names: ABX-900; ABX-9xx

Latest Information Update: 28 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Janssen
Developer Aro Biotherapeutics
Class Antineoplastics
Mechanism of Action Epidermal growth factor receptor antagonists; Proto-oncogene protein c-met inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 May 2023 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA
03 Apr 2019 Preclinical trials in Non-small cell lung cancer in USA (unspecified route) before April 2019
03 Apr 2019 Aro Biotherapeutics plans a clinical trial for Non-small cell lung cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com